Shover Chelsea L, Humphreys Keith
Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, USA.
Cureus. 2020 Jun 17;12(6):e8671. doi: 10.7759/cureus.8671.
Many cannabidiol (CBD) retailers make unsupported medical claims about their product. In recent years, the U.S. Food and Drug Administration (FDA) has sent warning letters to CBD retailers who promoted CBD to treat Alzheimer's disease, cancer, diabetes, and other serious conditions for which there is no evidence of its efficacy as a treatment or preventive. Compliance with these warning letters has been low. During the novel coronavirus disease 2019 (COVID-19) pandemic, the FDA has begun sending more strongly worded warning letters that appear to have better compliance in that most of these companies have removed COVID-19-related claims. However, many continue to present other unsupported medical claims on other serious medical conditions like cancer, depression, addiction, and bone fractures, among many others. We argue that adopting a strategy of focused deterrence where the FDA prioritizes enforcement related to COVID-19 claims - but when COVID-19-related claims are found, pursues all other violations by that company - would present an opportunity to efficiently cut down on harmful claims overstating CBD's benefits.
许多大麻二酚（CBD）零售商对其产品提出毫无根据的医学宣称。近年来，美国食品药品监督管理局（FDA）已向那些宣传CBD可治疗阿尔茨海默病、癌症、糖尿病及其他严重疾病的CBD零售商发出警告信，而目前并无证据表明CBD对这些疾病具有治疗或预防功效。对这些警告信的遵守情况很低。在2019年新型冠状病毒病（COVID-19）大流行期间，FDA开始发出措辞更严厉的警告信，而遵守情况似乎更好，因为大多数这类公司已删除与COVID-19相关的宣称。然而，许多公司仍继续就癌症、抑郁症、成瘾和骨折等其他严重疾病提出其他毫无根据的医学宣称。我们认为，采取一种重点威慑策略，即FDA将与COVID-19宣称相关的执法工作列为优先事项——但当发现与COVID-19相关的宣称时，追究该公司的所有其他违规行为——将提供一个机会，以有效减少夸大CBD益处的有害宣称。
